Why medical affairs is the next frontier for pharma brands

MM+M stands for “Medical, Marketing and Media,” representing the primary pillars of our coverage. But maybe there’s room for a fourth pillar, or at least a tweak to the first one: “Medical Affairs.”

Today’s episode is going to delve into medical affairs, which have risen in prominence over the past decade to become a key function for drugmakers and their agency partners. As today’s guests will discuss in greater detail, medical affairs is at the center of the venn diagram between R&D and commercial teams

I’m pleased to be joined by Renu Juneja, ADPAL president and former medical affairs lead at Johnson & Johnson, as well as my fellow Haymarket Media colleague Tammy Chernin, SVP of strategic and scientific services at PRI Healthcare Solutions.

These two walk us through where medical affairs stands in 2026, why pharma companies are increasingly prioritizing it for their business and where there is room for improvement as its profile continues to ascend.

As for Trends, I’ll be joined by editor-at-large Steve Madden and reporter Bella Czajkowski to talk about Breast Cancer Awareness Month, including newly launched initiatives, reupped ad campaigns as well as the evolving narrative around cancer care.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.